Norway Vaccine Market Size & Outlook, 2023-2030
Norway vaccine market, 2018-2030 (US$M)
Related Markets
Norway vaccine market highlights
- The Norway vaccine market generated a revenue of USD 182.4 million in 2023 and is expected to reach USD 253.3 million by 2030.
- The Norway market is expected to grow at a CAGR of 4.8% from 2024 to 2030.
- In terms of segment, subunit vaccines was the largest revenue generating type in 2023.
- Subunit Vaccines is the most lucrative type segment registering the fastest growth during the forecast period.
Vaccine market data book summary
| Market revenue in 2023 | USD 182.4 million |
| Market revenue in 2030 | USD 253.3 million |
| Growth rate | 4.8% (CAGR from 2023 to 2030) |
| Largest segment | Subunit vaccines |
| Fastest growing segment | Subunit Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Subunit Vaccines, Inactivated, Live Attenuated, MRNA vaccines, Viral vector vaccines |
| Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
Other key industry trends
- In terms of revenue, Norway accounted for 0.2% of the global vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany vaccine market is projected to lead the regional market in terms of revenue in 2030.
- Denmark is the fastest growing regional market in Europe and is projected to reach USD 320.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Vaccine Market Scope
Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine market will help companies and investors design strategic landscapes.
Subunit vaccines was the largest segment with a revenue share of 34.1% in 2023. Horizon Databook has segmented the Norway vaccine market based on subunit vaccines, inactivated, live attenuated, mrna vaccines, viral vector vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
In Norway, the public healthcare system and private health insurance are available. Most of the population of the country is covered by the public health insurance system. The quality of insurance service when it comes to private versus public is the same.
The healthcare system in Norway follows the principles of free choice of providers and universal access decentralization. It is financed by co-payments, taxation, and income related to employee & employer contributions. All citizens of Norway are covered under the national insurance scheme supervised by the Norwegian Health Economics Administration and private medical insurance companies.
The National Insurance Scheme (NIS) covers expenses for medical supplies and medicines prescribed for outpatient use. The coverage is limited to the treatment of severe illnesses or risk factors that may cause or aggravate serious illnesses. Co-pay of up to USD 246 may also be required for blue prescriptions.
Reasons to subscribe to Norway vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway vaccine market databook
-
Our clientele includes a mix of vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Norway vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway vaccine market size, by type, 2018-2030 (US$M)
Norway Vaccine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
